Pure Global
NCT05712642

A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

A Dosing Study of Two Different Doses (0.3125mg Versus 0.625mg) Intravitreal Bevacizumab for Type 1 ROP (Retinopathy of Prematurity)
Cairo University·Phase 3·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Retinopathy of Prematurity
Drug/Device/Intervention
Intravitreal Bevacizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Cairo University
Location
Cairo, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Feb 01, 2020
End date
Jan 28, 2021
Enrollment
19 participants
Primary outcome

Change in the serum systemic VEGF pre- and post- intravitreal injection of bevacizumab in both groups.,The number of infants without need for rescue therapy until 60 weeks of postmenstrual age after initial treatment.

Summary

The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab
 is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :
 
 Serum Systemic VEGF levels. Retinal Vascularization.

ICD-10 classifications
Retinopathy of prematurityOther proliferative retinopathyBackground retinopathy and retinal vascular changesDiabetic retinopathyRetinal disorder, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05712642
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05712642 through Pure Global AI's free database. This Phase 3 trial is sponsored by Cairo University and is currently Completed. The study focuses on Retinopathy of Prematurity. Target enrollment is 19 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.